810 - 1708 Dolphin Avenue
64 articles with Sernova Corp.
Sernova to Webcast Live at Life Sciences Investor Forum March 25thSernova invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com
Sernova Corp. (OTCQB:SEOVF)(TSX-V:SVA)(FSE/XETRA:PSH), a leading clinical-stage company focused on developing regenerative medicine therapeutics company, today announced that Dr. Philip Toleikis, President and CEO will present live at LifeSciencesInvestorForum.com on March 25 th . DATE: Thursday, March 25 th TIME: 10:30am ET
10/25/2019Pharma and life sciences companies strengthen their executive and leadership teams with this week's appointments.
Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes
Findings further validate Cell Pouch and therapeutic cell performance in
8/22/2019Companies from across the globe provide updates on their business and pipelines.
Sernova Corp., a clinical-stage regenerative medicine company, is pleased to announce that it has completed a first closing of $2,333,500 of its non-brokered private placement, of which $64,000 was closed under the “Existing Shareholder Exemption.”
Sernova's Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data
Sernova Corp. (TSXV:SVA) (FSE:PSH) (OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that its human Phase I/II clinical trial for type-1 diabetes is advancing with additional patients for device and cell transplantation.
7/18/2019Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
7/11/2019Companies from across Europe, Asia and around the globe share pipeline and business updates.
Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes
Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that in an interim analysis of its human Phase I/II clinical trial, Sernova's Cell Pouch transplanted with islet cells showed initial safety, as well as key efficacy measures, including glucose-stimulated C-peptide, insulin production and additional clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness.
Due to Oversubscription, Offering Increased to $2,700,000
Sernova Corp. announces that patient screening and recruitment has begun in its regenerative medicine US clinical trial for diabetic patients with hypoglycemia unawareness.
Sernova Receives U.S. FDA IND Allowance to Initiate a U.S. Clinical Trial of its Cell Pouch for the Treatment of Type 1 Diabetes
Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for tT1D in individuals with hypoglycemia unawareness.
Sernova Corp.-HemAcure Consortium Announce Significant Progress In Development Of ‘First In World’ Regenerative Medicine Therapy For Treatment Of Hemophilia A Patients
Sernova Corp. Honoured As Member Of The "2016 TSX Venture 50" And Ranked #4 In Life Sciences And Clean Technologies